Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

Merck & Co. Inc. has turned to Asia for a second time to get into the GLP-1 market, this time to Shanghai-based Hansoh ...

By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals' dominance in the GLP-1 ...

The Chinese Communist Party intends to add more nuclear arms to its growing arsenal while expanding its global influence and ...

Russia said it has developed a cancer vaccine that will be distributed to Russian patients for free starting in early 2025 — ...

Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named ...

Looking for the best dividend stocks for 2025? Review this list of potential stock picks to help increase your passive income ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Merck & Co. is doubling down on getting into the white-hot weight-loss drug market, scooping up a pill developed in China. Merck said Wednesday it will pay Hansoh Pharma $112 million upfront for the ...

See how Checkpoint Therapeutics, Inc.'s FDA-approved Unloxcyt drug for cSCC is set to disrupt the market with innovative ...

The Fed is widely expected to reduce interest rates by 25 basis points at its meeting. With a rate cut broadly priced in, the ...

The Johnson & Johnson drug Darzalex showed promise in helping keep a precancerous condition from progressing to the blood ...